GGrantIndex
Sort

51,593 grants matching hepatitis

Pre-clinical testing of a novel immunotherapy for HTLV-induced neurologic disease

$431,433
Pooja Jain · Drexel University · R01 · FY2021 · NS

Pre-clinical testing of a novel immunotherapy for HTLV-induced neurologic disease

$431,433
Pooja Jain · Drexel University · R01 · FY2019 · NS

Pre-clinical testing of a novel immunotherapy for HTLV-induced neurologic disease

$431,433
Pooja Jain · Drexel University · R01 · FY2020 · NS

Regulation of host innate and adaptive immunity by bacterial type III effectors

$431,414
James B Bliska · Dartmouth College · R01 · FY2023 · AI

Mechanisms Used by NKT Cells in the Control of Liver Tumors

$431,351
Robert Wiltrout · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA

ONTOGENY OF HEPATIC ION TRANSPORT

$431,335
Mount Sinai School Of Medicine Of Nyu · R37 · FY2002 · HD

Randomized Trial of an HIV Navigation Program for Early Palliative Care

$431,322
Jacquelyn Slomka · Case Western Reserve University · R01 · FY2012 · NR

Mechanistic enzymology of quinolinic acid biosynthesis

$431,275
Tadhg P. Begley · Cornell University · R01 · FY2007 · GM

Mechanism Of Interferon Induction By The Hepatitis C Virus

$431,168
Francis Vincent Chisari · University Of Washington · U19 · FY2013 · AI

Impact of host protein dynamics on picornavirus RNA 5’ noncoding region functions

$431,165
Bert L. Semler · University Of California-Irvine · R01 · FY2018 · AI

Regulation of Hepatic Insulin Extraction

$431,102
Washington University · R37 · FY2003 · DK

HCV Replication and Immune Response in HIV Coinfection

$430,973
University Of Washington · R01 · FY2004 · AI

Southern California Research Center for ALPD and Cirrhosis

$430,973
Hidekazu Tsukamoto · University Of Southern California · P50 · FY2024 · AA

Novel therapy targeting refractory colon cancer

$430,907
Ping-Ying Pan · Methodist Hospital Research Institute · R01 · FY2017 · CA

Impact of Hypothermia on Midazolam and Morphine Pharmacokinetics

$430,818
Athena F Zuppa · Children'S Hosp Of Philadelphia · R01 · FY2012 · HL

Tuberous Sclerosis-Pathway and Pathogenesis

$430,816
David J. Kwiatkowski · Brigham And Women'S Hospital · P01 · FY2008 · CA

Regulation of host innate and adaptive immunity by bacterial type III effectors

$430,790
James B Bliska · Dartmouth College · R01 · FY2024 · AI

Mechanisms for SIV evasion of vaccine immunity: Role of FasL-mediated cell death

$430,779
Charles David Pauza · University Of Maryland Baltimore · R01 · FY2007 · AI

CDPH OA 2011-2015 National HIV Behavioral Surveillance System and Hepatitis Testi

$430,759
Karen Elizabeth Mark · California Department Of Public Health · U1B · FY2011 · PS

OBESITY AND NONALCOHOLIC FATTY LIVER DISEASE

$430,721
Samuel Klein · Washington University · R01 · FY2008 · DK

Gene Therapy for Hemophilia Using Muscle-Expressed FVIIa

$430,683
Katherine A High · Children'S Hosp Of Philadelphia · P01 · FY2013 · HL

HIV and Drug Use in Georgian Women

$430,663
Hendree E. Jones · Research Triangle Institute · R01 · FY2010 · DA

CARD14 is essential for hepatitis C virus replication and activation of NFKB

$430,650
Timothy L Tellinghuisen · Scripps Florida · R01 · FY2012 · DK

CARD14 is essential for hepatitis C virus replication and activation of NFKB

$430,650
Timothy L Tellinghuisen · Scripps Florida · R01 · FY2014 · DK

CARD14 is essential for hepatitis C virus replication and activation of NFKB

$430,650
Timothy L Tellinghuisen · Scripps Florida · R01 · FY2015 · DK